CASE STUDY SUMMARY

Dry Eyes - Case Study Summary - 9 Patients

Sterile D-MAPPS™ Derived Ophthalmic Solution (Decellularized - Multiple Allogeneic Proteins Paracrine Signaling)

About

A clinical case study was performed by a licensed optometrist, who specializes in the treatment of Dry Eye Syndrome. Sterile D-MAPPS™ Derived Ophthalmic Solution was supplied to a select group of patients suffering from the discomfort and pain often accompanied with dry eyes.

Nine subjects, one drop each eye BIDx30 days, added to their current prescribed treatments with an age range of 40-90 years, the average age being 70 years old.

The study included the following visual conditions:

1. Glaucoma
2. Chronic Dry Eye
3. Moderate Dry Eye
4. Mild Dry Eye
5. Sjogrens Disease
6. Declining sight
7. Ankylosing spondylitis (possible)

The following observations were tracked and recorded:

1. OSDI Scores
2. Visual Acuity
3. Redness
4. Staining degree
5. Tear Break-up Times
6. Appearance
7. Artificial Tears frequency of use
8. Patient comments

*Clinical Data Provided by one of our in-network physicians.

Results

OSDI scores:

Showed consistent improvement in all 9 patients, subjectively and objectively.
Example: base score was 47.7; after 2 weeks of treatment the score was reduced to 35; after 3 weeks, down to 27.

Visual Acuity:

- Improvement was an unanticipated benefit of the therapy
- Improvement in distance, visual clarity, and reading ability
- Improvements of one to several lines on the Snellen Eye Chart

Visual acuity seemed to correlate to

- Improved corneal epithelial integrity levels
- Improved corneal surface irregularities

Redness:

8 of 9 participants noted improvement in level of redness

Staining levels as rated by the Oxford Method:

- Improvement in all participants
- One moderate dry eye participant showed no signs of dry eyes after 30 days

Tear Break Up Times (TBUT):

Sterile D-MAPPS™ Derived Ophthalmic Solution persists on the ocular surface for 90 seconds therefore is likely to have a positive effect on TBUT. TBUT studies underway to quantify degree of improvements.

Symptom Improvements:

Within two weeks of initiating therapy 8 out of 9 participants demonstrated improvements

Artificial Tear Usage:

- All participants reduced their usage of artificial tears
- One participant stopped using artificial tears completely after 3 weeks

The following patient statements were recorded throughout the study and are not the opinion of the study leader:

- "It sure is worthwhile."
- "I am totally amazed."
- "This is really worth it."
- "I forget about my eyes now!"
- "My eye are 95% better now than before."
- "I can stay up longer at night than I could before."
- "My eyes do not play out as quickly as they did before."
- "I am able to be on the computer at night, and before I could not think about it."
- "I had a good eye weekend and was able to be around a campfire and everything."
- "I have read two books in the last week and I have not been able to do that for a long time."

To learn more about Regener-Eyes®, please call us at 877-206-0706 or visit us at www.mydryeyes.org